City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  389  Clinical trial(s) found  (Page 1 of 16 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 18165

Principal Investigator: David Snyder, MD
Sponsor: Institutional

Title:  Individual Patient Supply of Oral Pacritinib for a Patient (RG) with Thrombocytopenia and Primary Myelofibrosis

COH Protocol Number: 18151

Principal Investigator: Linda Malkas, PhD
Sponsor: Institutional

Title:  CTSA Grant Proposal Data Gathering

COH Protocol Number: 18137 ClinicalTrials.gov Number: NCT02609776

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer

COH Protocol Number: 18116 ClinicalTrials.gov Number: NCT03410927

Principal Investigator: Sumanta Pal, MD
Sponsor: Industrial

Title:  A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Subjects with Advanced Solid Tumors with HER2 or HER3 Abnormalities

COH Protocol Number: 18115 ClinicalTrials.gov Number: NCT01901094

Principal Investigator: Lisa Yee, MD
Sponsor: Cooperative Group

Title:  Alliance A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

COH Protocol Number: 18101 ClinicalTrials.gov Number: NCT03153462

Principal Investigator: L. elizabeth Budde, MD, PhD
Sponsor: Industrial

Title:  A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma

COH Protocol Number: 18080

Principal Investigator: Finly Zachariah, MD
Sponsor: NCI Approved External Peer Review

Title:  Comparative Effectiveness of Early Integrated Telehealth versus In-Person Palliative Care for Patients with Advanced Lung Cancer (Short Name: REACH PC)

COH Protocol Number: 18065 ClinicalTrials.gov Number: NCT03007147

Principal Investigator: Weili Sun, MD, PhD
Sponsor: Cooperative Group

Title:  COG AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

COH Protocol Number: 18058 ClinicalTrials.gov Number: NCT03189030

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1 Safety and Tolerability Study of Personalized Live, Attenuated, Double-Deleted Listeria monocytogenes (pLADD) Immunotherapy in Adults with Metastatic Colorectal Cancer

COH Protocol Number: 18056 ClinicalTrials.gov Number: NCT03406949

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory B7-H3-Expressing Tumors

COH Protocol Number: 18044

Principal Investigator: Victoria Seewaldt, MD
Sponsor: Institutional

Title:  Reducing Cancer and Chronic Disease Risk in Underserved Communities: Eat, Move, Live Community Program

COH Protocol Number: 18040 ClinicalTrials.gov Number: NCT03321643

Principal Investigator: Alex Herrera, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-96, NCI#10126: A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination with Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma

COH Protocol Number: 18030 ClinicalTrials.gov Number: NCT03258554

Principal Investigator: Sagus Sampath, MD
Sponsor: Cooperative Group

Title:  NRG Oncology NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

COH Protocol Number: 18029 ClinicalTrials.gov Number: NCT03556228

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma

COH Protocol Number: 18023 ClinicalTrials.gov Number: NCT03207256

Principal Investigator: Tanya Siddiqi, MD
Sponsor: Industrial

Title:  An Open Label Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials with B-cell Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia

COH Protocol Number: 18022 ClinicalTrials.gov Number: NCT03372057

Principal Investigator: Jasmine Zain, MD
Sponsor: Industrial

Title:  A Multi-Center, Phase 2, Open-Label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T cell Lymphoma (PTCL)

COH Protocol Number: 18011

Principal Investigator: Lily Lai, MD
Sponsor: Institutional

Title:  Application of Neural Networks to Improve on Polyp Discrimination at Colonoscopy: A Pilot Study

COH Protocol Number: 17509 ClinicalTrials.gov Number: NCT03439280

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenecity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma

COH Protocol Number: 17507

Principal Investigator: Sanjeet Dadwal, MD
Sponsor: Institutional

Title:  Exploratory Analysis of Pre and Post-AlloHCT Microbial Communities in Patients with Acute Myelogenous Leukemia, a Longitudinal and Cross Sectional Pilot Study

COH Protocol Number: 17505 ClinicalTrials.gov Number: NCT03494569

Principal Investigator: Monzr Al malki, MD
Sponsor: Institutional

Title:  Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) Combined with Fludarabine and Melphalan as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome

COH Protocol Number: 17502 ClinicalTrials.gov Number: NCT03422627

Principal Investigator: Amandeep Salhotra, MD
Sponsor: Industrial

Title:  A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 592 in Adult Subjects With Steroid Refractory Chronic Graft versus Host Disease

COH Protocol Number: 17496

Principal Investigator: Benjamin Djulbegovic, MD
Sponsor: NCI Approved External Peer Review

Title:  Evaluation of the Group Decision-making Process of Clinical Guidelines Panels

COH Protocol Number: 17494 ClinicalTrials.gov Number: NCT03384940

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 2, Multicenter, Open-Label Study of DS-8201a in Subjects with HER2-Expressing Advanced Colorectal Cancer

COH Protocol Number: 17493 ClinicalTrials.gov Number: NCT03201458

Principal Investigator: Vincent Chung, MD
Sponsor: NCI Approved External Peer Review

Title:  PHII-165, NCI#10139: A Randomized Phase 2 Study of Atezolizumab in Combination with Cobimetinib versus Atezolizumab Monotherapy in Participants with Unresectable Cholangiocarcinoma

COH Protocol Number: 17491

Principal Investigator: Saro Armenian, DO
Sponsor: Institutional

Title:  Multi-Institutional Pilot Study to Assess the Needs of Childhood Cancer Survivors (CCS) Followed in Long-term Survivorship Clinics

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.